New combo therapy aims to boost remission in Hard-to-Treat lymphoma
NCT ID NCT07711483
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This phase 2 trial tests whether a combination of the targeted drug glofitamab with chemotherapy (gemcitabine and oxaliplatin) can improve the effectiveness of a CAR-T cell therapy called lisocabtagene maraleucel in people with relapsed or refractory aggressive B-cell lymphomas. Participants first receive the drug combination to shrink their cancer, then undergo CAR-T cell infusion. The study measures how many patients achieve complete remission and how long the effects last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of glofitamab, gemcitabine, oxaliplatin, and lisocabtagene maraleucel (a CAR-T cell therapy)
- What this could lead to
- If successful, this approach could improve the chance of complete remission for people with hard-to-treat B-cell lymphomas who have not responded to standard treatments.
- What could go wrong
- This is a phase 2 trial with a small number of participants, so results may not apply to everyone. The combination therapy carries risks of serious side effects, including immune reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the key to better CAR-T therapy lie in the gut?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a drug duo outsmart resistant lymphomas?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- New PET tracer could sharpen diagnosis of blood cancers
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope